Nalaganje...
Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK and ROS1 genomic alterations via comprehensive genomic profiling
INTRODUCTION: Crizotinib is an oral multitargeted tyrosine kinase inhibitor (TKI) with activity against lung cancers driven by ALK-rearrangements, ROS1-rearrangements and MET-amplification. Comprehensive genomic profiling (CGP) based on clinical next generation sequencing (NGS) can detect crizotinib...
Shranjeno v:
| izdano v: | Clin Lung Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4418215/ https://ncbi.nlm.nih.gov/pubmed/25922291 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2015.03.002 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|